Status:
TERMINATED
Prognosis and Therapeutic Biomarkers for Glioblastoma Patients
Lead Sponsor:
Baylor Research Institute
Conditions:
Glioblastoma
Eligibility:
All Genders
22+ years
Brief Summary
The purpose of this study is to investigate if the potential biomarkers identified could be used for facilitating the diagnosis and prognosis of patients with glioblastoma (GBM).
Detailed Description
The objective of this proposed study is to determine the expression levels of a panel of markers including CD133, CD44, ABCC3, TNFRSF1A, AKT1, IDH2, and MGMT in GBM tissues and the CSF, blood, and sal...
Eligibility Criteria
Inclusion
- 22 years old
- Control Group (only patients evaluated for neurological disorders whose evaluation require a lumbar puncture)
- Non-Control Group - Diagnosed with GBM (Glioblastoma)
Exclusion
- Pregnancy
- Infectious Disease to include cold, flu, HIV, etc.
- Blood Disorder (example:low platelets, anemia, thrombosis)
- Vascular Malformations
Key Trial Info
Start Date :
September 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 25 2019
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT03403803
Start Date
September 1 2017
End Date
March 25 2019
Last Update
March 27 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Baylor Scott and White Medical Center
Temple, Texas, United States, 76508